Bioten Co., Ltd.
KKRX:2891702,850.00
KRW
-140.00
(-4.68%)
ISIN
KR7289170003
Return %
Stock
S&P 500
1Y
-16.18
14.39
3Y
-15.68
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Jeongeup-si South Korea
- IPO Date
- Oct 13, 2023
- Website
- bioten.co.kr
- Similar Companies
- Business
- Bioten Co., Ltd. is a South Korea-based biotechnology company that develops, manufactures, and commercializes water-soluble natural bio-active compounds, functional health foods, pharmaceutical raw materials, and animal healthcare products. Founded in 2014 and headquartered in Iksan, South Korea, the company operates across the nutraceutical, veterinary nutrition, bio-cosmetic, and biopharmaceutical sectors. The company operates through four primary business segments: Functional Health Foods, Animal Health and Nutrition, Bio-Cosmetic Ingredients, and Bio-Pharmaceutical Materials. Its comprehensive product and service portfolio includes water-soluble curcumin formulations and dietary supplements marketed under the Tencurmin brand; condition-specific health functional foods targeting immune enhancement, liver protection, anti-inflammatory support, and metabolic regulation; bio-converted and nano-solubilized natural extract ingredients including water-soluble quercetin, resveratrol, and pterostilbene; functional animal feed additives, digestive enhancers, and natural antibiotic-alternative immune stimulants for livestock, poultry, aquaculture, and companion animals; bioactive cosmetic raw materials with antioxidant, anti-aging, and skin-brightening functionalities; and contract development and manufacturing (CDMO), original equipment manufacturing (OEM), and original design manufacturing (ODM) services for global nutraceutical and food enterprises. Bioten Co., Ltd. serves a diverse institutional and consumer client base comprising pharmaceutical manufacturers, dietary supplement brand owners, animal feed producers, cosmetic companies, and healthcare retailers across South Korea, North America, Southeast Asia, and Europe. The company maintains its research and development center and Good Manufacturing Practice (GMP)-certified mass-production facilities within the Korea National Food Cluster in Jeollabuk-do, South Korea, and collaborates closely with national research organizations such as the Korea Research Institute of Bioscience and Biotechnology. In recent developments, Bioten Co., Ltd. has advanced the therapeutic research and preclinical validation of its proprietary water-soluble curcumin formulations for respiratory, inflammatory, and metabolic disease indications in collaboration with domestic university hospitals and national bio-research institutes. The company has expanded its commercial market reach through new strategic distribution partnerships and cross-border supply agreements to export functional health ingredients and finished formulations across North America and Southeast Asia. Furthermore, Bioten Co., Ltd. has upgraded its manufacturing and extraction capacity at its Iksan facility to support expanded OEM and ODM contracts, launched a new generation of functional feed supplements tailored for sustainable and antibiotic-free livestock farming, and broadened its intellectual property portfolio with newly registered patents covering natural active ingredient nano-emulsification and bio-conversion platform technologies.